Description

Abbott Lab’s 13% Cancer Diagnostics Growth Adds A Powerful Second Engine Beyond CGM!

Abbott’s second quarter of 2026 results showed a 4.8% comparable sales growth, marking an acceleration from the previous two quarters, alongside adjusted earnings per share (EPS) of $1.31 which surpassed both the midpoint of company guidance and consensus estimates. Management reaffirmed full-year guidance with expected comparable sales growth of 6.5% to 7.5% and raised the EPS range to $5.45–$5.60. The company highlighted progress in its product pipeline, including enrollment completion in the TECTONIC coronary IVL trial, an FDA submission for the Amulet 360 device, and obtaining CE Mark for Libre Duo, a dual glucose-ketone sensor. Several important clinical trials are scheduled to begin patient enrollment in late 2026, supporting future product launches across cardiovascular and diagnostic portfolios. By segment, Diagnostics reflected durable demand with U.S. Core Laboratory sales rising 7.5%, despite an 8% decline in Rapid and Molecular Diagnostics due to a weaker respiratory virus testing season.